araag2/TREC_Precision-Medicine huggingface dataset:
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Immune Response in Lung Cancer

Summary: This study is designed to evaluate the importance of the immune cells localization (distribution) between malignant tumor islets and surrounding stroma and to investigate the associations between these immune cells as well as cytokines and clinicopathological and prognostic factors of non-small cell lung cancer (NSCLC) patients.


Eligibility: Inclusion Criteria:
  -  Eastern Cooperative Oncology Group (ECOG) score of 0-1
  -  Patients with histologically documented non-small cell lung cancer
  -  Control group - patients without non-small cell lung cancer
  -  Written (signed) Informed Consent to participate in the study
  Exclusion Criteria:
  -  Any other malignancies within 5 years
  -  Any unstable systemic disease (including active infections, significant cardiovascular disease)
  -  Prior chemotherapy or radiotherapy
  -  Autoimmune disease
  -  Nursing or pregnant women

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: The Roles of Age, Comorbidity, and Telomere Length in Lung Cancer Treatment and Prognosis

Summary: The investigators hypothesize that the age-adjusted telomere length in lung cancer patients before chemotherapy may be correlated to comorbidity status and predict outcome. The change of telomere length shortening after chemotherapy may relate to treatment side effect and treatment response.

Detailed description: Except chemotherapy, telomere shortening were also related to a variety of cellular stress, including hydrogen peroxide, UV, and x-irradiation, transforming growth factor-beta, overexpression of oncogenes such as Ha-Ras. The cellular stress induced telomere shortening and/or telomere dysfunction and promote accelerated senescence in normal and malignant cells. Oxidative stress, which presented in several chronic inflammatory diseases, such as atherosclerosis, coronary artery disease, and chronic obstructive airway disease, was also found to be correlated with telomere shortening.

Eligibility: Inclusion Criteria:
  1. Patients who are newly diagnosed as lung cancer and prepared for scheduled chemotherapy.
  2. The diagnosis is based on pathology via surgical specimen, or biopsy; or cytology via lung, lymph node aspiration or effusion study.
  Exclusion criteria:
  includes clinical diagnosis of lung cancer without pathology or cytology proving, combined with other type malignancy, and expected short survival time less than one month.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Effectiveness of a Preoperative Pulmonary Rehabilitation Program in Patients Awaiting Lung Resection

Summary: The purpose of this study is to establish the effectiveness of a preoperative pulmonary rehabilitation program in patients awaiting lung resection for lung cancer by Video-assisted thoracic surgery in order to improve exercise tolerance and quality of life. The investigators hypothesized that a pulmonary rehabilitation program including both endurance and strength training may improve exercise tolerance and quality of life measured with a submaximal exercise test and a quality of life questionnaire respectively.


Eligibility: Inclusion Criteria:
  -  Diagnosis confirmed or suspected of lung cancer (either primary or metastatic)
  -  Be on the waiting list for lung resection by Video-assisted thoracic surgery
  -  Present at least one of the next conditions: Forced Expiratory Volume in 1 second (FEV1)<80% of predicted and/or Body Mass Index > 30 or/and >80 years old and/or two or more comorbidities (Arterial Hypertension, Chronic Obstructive Pulmonary Disease, Coronary Disease, Diabetes, Renal Failure and/or cancer.
  -  No smoking at the time of recruitment
  -  Signed Informed Consent
  Exclusion Criteria:
  -  Chemotherapy or Radiotherapy in the previous 6 months before the Rehabilitation program.
  -  Thoracotomies or pneumonectomies.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: EBUS/Spectrum Analysis

Summary: To evaluate the clinical benefit of spectrum analysis of endobronchial ultrasound images of lymph nodes during EBUS TBNA for lymph node staging in patients with lung cancer.


Eligibility: Inclusion Criteria:
  -  Ages 18 years or older
  -  Patients with known or suspected lung cancer who require EBUS-TBNA for lymph node staging
  Exclusion Criteria:
  -  Patients who are deemed on clinical grounds not to be medically fit for a bronchoscopy
  -  Inability to give informed consent
  -  Patients who are pregnant

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Gossypol Combined With Docetaxel and Cisplatin Scheme in Advanced Non Small-cell Lung Cancers With APE1 High Expression

Summary: The investigators' experimental study found that gossypol was the natural inhibitor of apyrimidinic endonuclease 1 (APE1) and clinical study observed that high expression of APE1 was relative to the platinum-resistance in non-small cell lung cancer. Thus the purpose of this study is to find out whether gossypol can improve the sensitivity of cisplatin-based chemotherapy in the non-small cell lung cancer with apurinic apyrimidinic endonuclease 1 (APE1) high expression


Eligibility: Inclusion Criteria:
  -  Histologic or cytologic diagnosis of NSCLC, Stage IIIB/IV.
  -  Males or females between 18 Years to 75 Years.
  -  No prior cisplatin-based chemotherapy, if the surgery or radiotherapy has been administered, the interval is at least above four weeks. The interval for targeted therapy such as EGFR TKI is above 2 weeks.
  -  Performance status of 0, 1 on the ECOG criteria. Expected survival is above three months.
  -  At least one unidimensional measurable lesion meeting Response Evaluation Criteria in Solid Tumors (RECIST. 2000).
  -  Patients can have the brain / meningeal metastasis history, but the metastasis must be treated by operation or radiotherapy), and clinically stable for at least 2 months.
  -  Adequate hematologic (neutrophil count >= 1,500/uL, platelets >= 100,000/uL), hepatic (transaminase =< upper normal limit(UNL)x2.5, bilirubin level =< UNLx1.5), and renal (creatinine =< UNL) function.
  -  Patient compliance that allow adequate follow-up. Informed consent from patient or patient's relative.
  -  APE1 IHC (++ or +++).
  -  If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device [IUD], birth control pills, or barrier device) during and for 2 months after trial. If male, use of an approved contraceptive method during the study and 2 months afterwards. Females with childbearing potential must have a urine negative HCG test within 7 days prior to the study enrollment.
  -  No concomitant prescriptions including cyclosporin A, valproic acid, phenobarbital, phenytoin, ketoconazole.
  Exclusion Criteria:
  -  Inability to comply with protocol or study procedures.
  -  Medically uncontrolled serious heart, lung, neurological, psychological, metabolic disease.
  -  Second primary malignancy that is clinically detectable at the time of consideration for study enrollment.
  -  Pregnant or breast-feeding.
  -  Enrollment in other study within 30 days.
  -  Brain metastasis with symptoms.
  -  Hypokalemic periodic paralysis history.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Telephone Support Program for Lung Cancer Patients and Their Family Caregivers

Summary: The goal of this project is to examine the physical and psychological health benefits of a novel, telephone-delivered symptom management intervention for advanced lung cancer patients and their family caregivers.


Eligibility: Inclusion Criteria:
  -  Clinical diagnosis of lung cancer
  -  Must be able to speak and read English
  Exclusion Criteria:
  -  No working phone service
  -  Does not have a family caregiver

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Circulating Fibrocytes in Non-small Cell Lung Cancer.

Summary: The investigators will collect fibrocytes (CD45+Col-1+) in patients with non-small cell lung cancer (NSCLC). The investigators hypothesize that patients with NSCLC experience expansion of immunosuppressive fibrocytes, which are predicted to augment tumor growth by mediating immune escape in NSCLC patients.

Detailed description: Fibrocytes have been described in both mice and humans, where they bear a hematopoietic progenitor phenotype (CD45+Col-1+). Fibrocytes have previously been described in murine cancer, implicated as mediators of tumor immune escape. In this study, the investigators will collect fibrocytes including CD45+Col-1+ expression. The cells express indoleamine oxidase, which is primarily responsible for their immunosuppressive properties. The investigators hypothesize that patients with non-small cell lung cancer experience expansion of immunosuppressive fibrocytes, which are predicted to augment tumor growth by mediating immune escape in non-small cell lung cancer patients.

Eligibility: Inclusion Criteria:
  -  Histologically or cytologically confirmed non-small cell lung cancer (NSCLC).
  Exclusion Criteria:
  -  Combination of other malignancy.
  -  Age less than 20 years (not include 20 years).
  -  Pregnancy.

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Determinants of Intensity of Care of Lung Cancer Patients With Organ Failure

Summary: Investigators will evaluate determinants of the patients' care type : palliative, medical or intensive care. The place of patient or family on care's decision will be noticed. Investigators will evaluate 3 month-survival and patients' feelings (visit with a psychologist) according to type of care they benefited.

Detailed description: Two hundred patients have to be enrolled in 2 years in the Grenoble Teaching Hospital and in the Saint Louis hospital in Paris between November 2010 and November 2012. Each lung cancer patient with at least one organ failure, admitted in emergency, thoracic oncology or directly in ICU will be included.
  The objectives are to identify patients' characteristics associated with proposition for intensive care unit admission and those associated with the decision of intensive care unit admission.

Eligibility: Inclusion Criteria:
  -  lung cancer
  -  Organ failure
  Exclusion Criteria:

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion

Summary: Patients with Malignant pleural effusion can be diagnosis advanced cancer. Currently recognized as the most reliable method to control malignant pleural effusion is pleural fixed or thoracic catheter drainage. The most effective pleural fixed agent is pulvis talci, but there are about 30% relapse rate. Thoracic drainage can lead to some complications, such as chest infections, catheter migration and blockage etc. The investigators need a reliable methods to solve dyspnea and other symptoms caused by malignant pleural effusion, and improve quality of life. The purpose of this study was to determine the efficacy and Safety of intrapleural Bevacizumab versus pulvis talci as treatment for malignant pleural effusions (MPE) in patients.

Detailed description: Background： Patients with Malignant pleural effusion can be diagnosis advanced cancer. Currently recognized as the most reliable method to control malignant pleural effusion is pleural fixed or thoracic catheter drainage. The most effective pleural fixed agent is pulvis talci, but there are about 30% relapse rate. Thoracic drainage can lead to some complications, such as chest infections, catheter migration and blockage etc. The investigators need a reliable methods to solve dyspnea and other symptoms caused by malignant pleural effusion, and improve quality of life. The purpose of this study was to determine the efficacy and Safety of intrapleural Bevacizumab versus pulvis talci as treatment for malignant pleural effusions (MPE) in patients.
  Methods:
  A unblended, randomized study to compare the inhibition of two treatment methods in malignant pleural effusion. Consecutive 183 patients were randomly assigned to two groups, A group is Bevacizumab200mg by intrapleural administration; B group is injected pulvis talci with closed thoracic drainage.

Eligibility: Inclusion Criteria:
  1. Diagnose malignant pleural effusions by:
  -  Diagnose malignant pleural neoplasms by histopathology
  -  Recurrent pleural effusion, Histologically or cytologically confirmed diagnosis of cancer
  2. Written informed consent
  Exclusion Criteria:
  1. <18years of age
  2. Expected survival <3 months
  3. Chest infection, chylothorax, pleurodesis or ipsilateral lung surgery once
  4. Planned chemotherapy
  5. Pregnancy or breast-feeding (women of child-bearing potential)
  6. Not signed informed consent or non-compliance with treatment protocols

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Summary: The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).


Eligibility: Inclusion Criteria:
  -  Ages eligible for study : 18 years to 74 years
  -  Genders eligible for study : Male and Female
  -  Diagnosed with T2DM
  -  Received diet and exercise therapy with or without metformin monotherapy
  -  HbA1c levels of between ≥ 7.0% and ≤ 10.0%
  -  Females of childbearing potential who are not pregnant and agree to use a reliable method of birth control
  -  Written informed consent must be obtained
  Exclusion Criteria:
  -  Pregnant or nursing (lactating) women
  -  Diagnosis of type 1 diabetes mellitus
  -  Uncontrolled diabetes defined as a FPG level of > 240 mg/dL
  -  A significant change in body weight in the 3 months before screening
  -  Any history of GI intolerance
  -  Personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC
  -  Known history of chronic pancreatitis
  -  A history of alcohol or drug abuse or drug addiction

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Effectiveness of Nursing Case Management for Lung Cancer Patients

Summary: The study is to investigate the effectiveness of nursing case management for lung cancer patients in a Taiwan medical center.

Detailed description: Purpose: The study is to investigate the effectiveness of nursing case management for lung cancer patients in a Taiwan medical center. The outcome variables include of percentages of patients accepted treatment in our medical center, average lengths of stay, unplanned re-admission rate, average admission times of emergency department per year, percentages of patients rejecting treatment, completing rate of treatment, withdrawing rate of treatment, improving rate of patients' treatment compliance, patients' satisfaction with healthcare, and staffs' satisfaction with case management.
  Methods: The study will employ a quasi-experimental research design. The patients with new-diagnosed lung cancer and accepting case management will be assigned to the experimental group； The patients with new-diagnosed lung cancer in the period of one year ago and without accepting case management will be assigned to the control group；The third group is the patients with non-new-diagnosed lung cancer and with accepting case management. The staffs are the doctors within the lung cancer medical team.
  The lung cancer case management database, patients' satisfaction questionnaire, and staffs' satisfaction questionnaire will be used to measure the effectiveness. Statistical software SPSS for Windows version 17.0 will be used to analyze the data.
  Expected results: The research outcome will to confirm the impact of case management on the lung cancer patients and could be the reference data for future cancer case management model.

Eligibility: Inclusion Criteria:
  -  patients with lung cancer
  Exclusion Criteria:
  -  younger than 20 years old

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes

Summary: The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a month under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).


Eligibility: Inclusion Criteria:
  -  Ages eligible for study : 18 years to 74 years
  -  Genders eligible for study : Male and Female
  -  Diagnosed with T2DM
  -  Taking a stable dose of metformin monotherapy
  -  HbA1c levels of between ≥ 7.0% and ≤ 10.0%
  -  Females of childbearing potential who are not pregnant and agree to use a reliable method of birth control
  -  Written informed consent must be obtained
  Exclusion Criteria:
  -  Pregnant or nursing (lactating) women
  -  Diagnosis of type 1 diabetes mellitus
  -  Uncontrolled diabetes defined as a FPG level of > 240 mg/dL at screening
  -  A significant change in body weight in the 3 months before screening
  -  Any history of GI intolerance
  -  Personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC
  -  Known history of acute or chronic pancreatitis
  -  A history of alcohol or drug abuse or drug addiction

Relevance to patient case: not relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.

Summary: Entrectinib (RXDX-101) is an orally available inhibitor of the tyrosine kinases TrkA (coded by the gene NTRK1), TrkB (coded by the gene NTRK2), TrkC (coded by the gene NTRK3), ROS1 (coded by the gene ROS1), and ALK (coded by the gene ALK). Molecular alterations to one or more of these targets are present in several different tumor types, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), prostate cancer, papillary thyroid cancer, pancreatic cancer, and neuroblastoma. Patients with locally advanced or metastatic cancer with a detectable molecular alteration in targets of interest may be eligible for enrollment.
  Phase 1 will assess safety and tolerability of entrectinib via standard dose escalation scheme and determine the recommended Phase 2 dose. Safety and efficacy will be assessed in the dose expansion portion of the study.


Eligibility: Key Inclusion Criteria:
  -  Histologically or cytologically confirmed diagnosis of locally advanced or metastatic solid tumors that have a NTRK1, NTRK2, NTRK3, ROS1, or ALK molecular alteration.
  -  Measurable disease according to RECIST version 1.1.
  -  Prior cancer therapy is allowed, including crizotinib, ceritinib, and investigational drugs.
  -  Prior radiotherapy is allowed
  -  Patients with controlled asymptomatic central nervous system involvement are allowed.
  -  Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer therapy to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 4.03 Grade less than or equal to 1.
  -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) ≤ 2.
  -  Adult patients age 18 years or older.
  -  Life expectancy of at least 3 months.
  Key Exclusion Criteria:
  -  Current participation in another therapeutic clinical trial.
  -  Prior treatment with entrectinib.
  -  History of prolonged QTc interval (e.g., repeated demonstration of a QTc interval > 450 milliseconds).
  -  History of additional risk factors for torsade de pointes (e.g., family history of long QT syndrome).
  -  Known active infections (bacterial, fungal, viral including HIV positivity).
  -  Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut syndrome) or other malabsorption syndromes that would impact on drug absorption.
  -  Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase inhibitor-induced pneumonitis.
  -  Peripheral neuropathy ≥ Grade 2.

Relevance to patient case: possibly relevant
Patient case: 58-year-old female with Lung cancer. Genetic variant: NTRK1. Other conditions: Depression, Hypertension, Diabetes.

Clinical trial: Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients

Summary: The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid carcinoma (MTC).


Eligibility: Inclusion Criteria:
  -  Japanese patients with ATC (Anaplastic thyroid carcinoma) or locally advanced or metastatic MTC (medullary thyroid carcinoma)
  -  Not a candidate for surgery or radiotherapy with curative intent
  -  Histologically or cytologically confirmed ATC or MTC
  -  Measurable or non-measurable disease (but clinically evaluable) according to RECIST 1.1.
  -  Age >= 18 years
  -  Adequate bone marrow, liver and renal function to be conducted within 14 days prior to treatment
  -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
  -  Life expectancy of at least 12 weeks
  Exclusion Criteria:
  -  Histologic subtypes of thyroid cancer other than anaplastic or medullary carcinoma
  -  Prior anti-cancer treatment with tyrosine kinase inhibitors, monoclonal antibodies (licensed or investigational) that target VEGF or VEGF (vascular endothelial growth factor) receptors or other targeted agents
  -  Prior chemotherapy for thyroid cancer (only one regimen is allowed)
  -  Major surgery, open biopsy, or significant traumatic injury within 30 days prior to enrollment in the study.
  -  Subjects with tracheal, bronchial or esophageal infiltration with significant risk of bleeding but without having received local treatment prior to enrollment in the study

Relevance to patient case: not relevant